NVIDIA-backed Iambic Therapeutics files for IPO - MobiHealthNews
Why now
Thesis: NVIDIA-backed biotech IPO tests AI-drug discovery appetite
Catalyst to watch: IPO pricing and first-day trading
Main risk: Weak biotech sentiment could sink offering
Why it matters
An NVIDIA-backed therapeutics company filing for IPO shows AI-drug-discovery capital formation continuing.
Sources
- googlenews · news.google.com · 2026-09-22 17:21 UTC